Advanced results of Fortelyzin® use in the FRIDOM1 study and real clinical practice

Advanced results of Fortelyzin® use in the FRIDOM1 study and real clinical practice

Aim. To study the effectiveness of Fortelyzin® in subgroups with different body weights in patients with ST-segment elevation acute myocardial infarction (STEMI) in the FRIDOM1 study and real clinical practice.Material and methods. Fortelyzin® was administered in a single-bolus dose of 15 mg over 10...

Full description

Saved in:
Bibliographic Details
Main Authors: V. A. Markov, D. V. Duplyakov, S. L. Konstantinov, G. V. Klein, S. B. Aksentiev, D. Yu. Platonov, E. V. Vyshlov, Е. A. Ponomarev, R. M. Rabinovich, E. L. Makarov, E. V. Kulibaba, D. S. Yunevich, O. V. Kritskaya, E. A. Baranov, O. B. Talibov, V. A. Kutsenko, A. A. Orlovsky, N. L. Vyazova, A. G. Koledinsky, A. M. Semenov, M. P. Semenov, E. B. Yarovaya, T. M. Uskach, R. M. Shakhnovich, S. N. Tereshchenko, S. S. Markin
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2022-09-01
Series:Российский кардиологический журнал
Subjects:
thrombolysis
fortelyzin®
stemi
single bolus
fridom1
Online Access:https://russjcardiol.elpub.ru/jour/article/view/5178
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://russjcardiol.elpub.ru/jour/article/view/5178

Similar Items